| Document |
Document Title |
|
JP2008518895A |
The present invention relates to oral solid dosage forms containing a very low dose of estradiol. The dosage forms are formulated in a manner so as to avoid degradation of the estradiol and to minimise the content of polyvinylpyrrolidone...
|
|
JP2008120839A |
To provide a compound useful for treating mammalian diseases characterized by undesired cell mitosis.A new estradiol derivative binds to tubulin, inhibits microtubule formation or exhibits anti-mitotic properties.
|
|
JP2008120840A |
To provide a compound useful for treating mammalian diseases characterized by undesired cell mitosis.A new estradiol derivative binds to tubulin, inhibits microtubule formation or exhibits anti-mitotic properties.
|
|
JP2008512425A |
To provide a pharmaceutical composition and gel containing testosterone, a method of using them, and more specifically, a hydroalcohol / alcohol-based pharmaceutical composition and gel containing testosterone. The compositions of the pr...
|
|
JPWO2006001471A1 |
Equation (I):A composition comprising the compound represented by, or a salt thereof or a physiologically hydrolyzable and acceptable ester thereof.
|
|
JP4070463B2 |
A method of producing 3-alkoxy-1,3,5(10)-triene-6-one-steroid derivatives having, in the steroid skeleton thereof, a partial structure of A- and B-rings represented by formula (2) : (wherein R represents an alkyl group, a cycloalkyl grou...
|
|
JP2008063345A |
To provide a medicinal composition containing 2-methoxyestradiol having 98% high purity.The 2-methoxyestradiol having 98% high purity is prepared by a synthetic or purification method. This highly pure 2-methoxyestradiol, lacking estroge...
|
|
JP2008058329A |
To the identify a substances that play a role in controlling brain amyloid-(A) levels in vivo.A kit for predicting the possibility of an amyloidosis increase in a test subject includes a means for observing the level of an estrogen compo...
|
|
JP2008505079A |
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for t...
|
|
JP2008504338A |
The invention relates to novel 2-substituted estra-1,3,5(10)-trien-17-ones of formula (I), wherein R2 is an C1-C8 alkyl saturated or unsaturated group, an C1-C5-alkyloxy group, an aralkyl- or alkylaryl rest, an -O-CnFmHo rest, wherein n=...
|
|
JP2008504329A |
The present invention relates to the use of specific steroid derivatives in the preparation of medicaments for the treatment or prevention and/or amelioration of disorders relating to pathological processes in lipid rafts.
|
|
JP2008504263A |
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for t...
|
|
JP2008502725A |
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for t...
|
|
JP4039683B2 |
A codrug composition of at least two drug compounds covalently linked to one another via a labile bond to form a single codrug composition, and methods of use of the codrug for the treatment of various medical conditions. The codrug may ...
|
|
JP2008500368A |
Compounds, compositions and methods for treating degenerative diseases and disorders are disclosed, the compounds having the following structure (I): including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherei...
|
|
JP4024734B2 |
|
|
JP2007536251A |
Methods and compositions for treating and/or preventing a pregnancy related disease or disorder are provided. The methods involve administration of 2-methoxyestradiol, or an analog thereof, to a subject. Also provided are methods for dia...
|
|
JP2007530573A |
Disclosed in embodiments herein is a method of treating chronic dry eye in a patient in need thereof, the method comprising topically administering to the patient Loteprednol etabonate in an ophthalmolically acceptable carrier.
|
|
JP4002438B2 |
The present invention concerns with steroid compounds of formula (I) wherein R<1> is cyclyhexyl or cycloheptyl, R<2> is hydrogen or C1-C6 alkyl, R<3> is hydrogen, C1-C6 alkyl or methylol, R<4> is hydrogen or hydroxymethylene and a pharma...
|
|
JP2007529426A |
Compositions and methods for treating mammalian diseases or conditions characterized by undesirable angiogenesis by administering an effective amount of a compound of the formulae: wherein Ra is selected from —OCH3, —OCH2CH3 or —CC...
|
|
JP2007528358A |
The treatment and/or prevention of depression by the co-administration of an estrogen with the progestin dienogest for HRT and/or contraception.
|
|
JP2007254476A |
To provide a new non-estrogenic derivative of estradiol which have no estrogenic activity and an anti-oxidative activity. The invention relates to the non-estrogenic estradiol derivatives with antioxidative activity, for example, such as...
|
|
JP3984315B2 |
The invention relates to a method of the preparation of a steroid derivative ketal according to the general formula I: wherein R1 is CH3 or C2H5; R2 is OH; R3 is H, CH3; C IDENTICAL CH, CH2Hal,, or CH2CN; or R2 and R3 together are O; R4 ...
|
|
JP3983796B2 |
This invention provides a simplified method for converting pregnan-3,20-dione compounds to 3 alpha -hydroxy,3 beta -substituted-pregnanes. By selective use of reagents the unprotected dione is converted chemoselectively and diastereosele...
|
|
JP2007238621A |
To provide a therapeutic antiviral preparation having improved pharmacological characteristics, a dosing regimen for a new antiviral compound not more troublesome than the conventional regimen, or an assay method determining the presence...
|
|
JP3977462B2 |
The invention relates to a 11-(substituted phenyl)-estra-4,9-diene derivative of formula I wherein A is a residue of a 5- or 6-membered ring containing 2 heteroatoms which are not connected to each other and independently selected from O...
|
|
JP2007231020A |
To provide a new compound which improves the lipid barrier penetrability of a biologically active substance comprising a fatty acid such as lipoic acid and simultaneously makes a biologically active substance comprising a different fatty...
|
|
JP2007210994A |
To obtain a steroid compound of a kind having an anti-progestin effect and a pharmaceutical value, to provide a method for preparing the steroid compound, to obtain a pharmaceutical composition for treating diseases associated with proge...
|
|
JP3960481B2 |
The invention relates to compounds of formula: wherein R1 is selected from the group consisting of fatty acid acyl groups of 12 to 30 carbon atoms and fatty alcohol groups of 12 to 30 carbon atoms, and wherein R2 is selected from the gro...
|
|
JP2007517878A |
The present invention is a di-steroidal prodrug of ethinyl estradiol according to formula I:
|
|
JP2007517877A |
The present invention is a di-steroidal prodrug of estradiol having the following formula:
|
|
JP2007517041A |
The present invention relates to compounds of the formula or pharmaceutically acceptable salts thereof useful for the prophylaxis and treatment of degenerative bone disorders and for the acceleration of bone healing.
|
|
JP2007515932A |
The present invention relates to a two part microbial process for the preparation of 7-oxo-5-androstene steroids of Formula III.
|
|
JP3934005B2 |
To provide a method for improvement of somatic cell gene therapy utilizing enhanced gene transduction, and to provide a cell group or a new constituent of enhancing the transduction of DNA into a cell through a retrovirus, and to provide...
|
|
JP2007512279A |
The present invention relates to the use of the ERbeta agonists 8beta-Vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-Fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-di
ol for production of medicaments for the prevention and/or t...
|
|
JP2007512361A |
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for t...
|
|
JP2007512223A |
A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a phosphodiesterase-4 inhibi...
|
|
JP2007512344A |
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for t...
|
|
JP3908162B2 |
A compound of general formula (I): wherein, for example, X<1> and X<2> independently represent a hydrogen atom, R represents a hydrogen atom or a protecting group for a hydroxyl group, R and R form an optionally protected -(C=O)- togethe...
|
|
JP3909870B2 |
PURPOSE: To provide the novel compounds useful as immunosuppressants, anti- inflammatory agents, antifungal agents, antiproliferative agents and antitumor agents. CONSTITUTION: By protecting an alcoholic site of paramycin with a protecti...
|
|
JP2007509839A |
A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an anticholinergic bronchodi...
|
|
JP2007508265A |
This invention relates to a method for preventing or delaying the progression of hormone receptor positive of hormone receptor unknown breast cancer in a patient by following estrogen antagonist therapy by subsequent therapy with an estr...
|
|
JP2007084499A |
To provide a method for oxidizing an alcohol compound, by which the oxidization reaction from an alcoholic hydroxyl group into a carbonyl group can be performed in mild conditions.This method for oxidizing the alcohol compound, comprisin...
|
|
JP2007507534A |
An extended triphasic oral contraceptive regimen is disclosed. According to the disclosed regimen, a combination of an estrogen and a progestin is administered for at least 42 consecutive days followed by a hormone-free period of from 4 ...
|
|
JP2007506761A |
The present invention relates to novel synthetic derivatives of triterpenes and the use of such derivatives as pharmaceuticals. The present invention is directed to novel compounds of Formula I: or pharmaceutically acceptable salt or est...
|
|
JP3895490B2 |
To treat asthma by inhibiting the linkage of animal AP-1 to DNA and the respiratory smooth muscle multiplication by administrating an effective dose of a specific steroid to animals. Asthma is treated by means of inhibiting the linkage o...
|
|
JP2007506805A |
Processes useful in the preparation of pharmaceutical compounds such as fulvestrant and processes for the preparation of fulvestrant.
|
|
JP2007063296A |
To provide a medicinal composition useful for treating human prostatic adenocarcinoma.The medicinal composition for treating human prostatic adenocarcinoma comprises a 5-α-reductase inhibiting compound of 17β-(N-t-butylcarboxamide)-5-Î...
|
|
JP2007505039A |
Described are drug formulations that increase regional delivery of the drugs to cells. Methods for reversibly increasing the hydrophobicity of a drug through hydrolytic ally labile attachment of a hydrophobic moiety and methods for deliv...
|
|
JP2006342180A |
To provide an animal chronic asthma medicine which inhibits the proliferation of airway smooth muscles, has airway smooth muscle-relaxing and bronchodilatating actions, and inhibits the secretion of inflammatory cytokine from airway epit...
|
